Overview
- Metsera said it accepted Pfizer’s offer worth up to $86.25 per share, including $65.60 in cash and up to $20.65 in contingent payments, valuing the deal at about $10 billion.
- The company cited a Federal Trade Commission letter warning that Novo Nordisk’s proposed two-step approach could violate premerger rules, calling Novo’s legal and regulatory risks unacceptable.
- Pfizer’s bid has already received FTC clearance, and the company said it expects to close shortly after Metsera’s Nov. 13 shareholder vote, subject to approval.
- A Delaware judge earlier denied Pfizer’s request to temporarily block Novo’s competing proposal, a ruling that preceded several bid increases from both suitors.
- The acquisition targets Metsera’s next‑generation obesity pipeline, including once‑monthly GLP‑1 candidate MET‑097i, as Pfizer and Novo vie for position in a fast-growing weight‑loss market.